ASXC Company Profile and Key Details

Q: Who are the executives of ASXC?

Mr. Shameze Rampertab B.Sc. MBA, CA, CPAExecutive Vice President & Chief Financial OfficerMr. Joshua B. WeingardChief Legal Officer & Sec.Mr. Paul Ziegler Jr., J.D.Vice President of SalesMs. Amanda OwensVice President of PeopleDr. Stephanie M. Fitts Ph.D.Vice President of Clinical, Quality and Regulatory AffairsMr. Ethan LoiselleVice President of Global MarketingMr. Anthony FernandoPres, Chief Executive Officer & DirectorMr. Ravi KommineniHead of Global Quality & Regulatory

AMEX : ASXC

Asensus Surgical

$0.35

0.0022+0.64%

At Close 4:00 PM

Not Actively Trading

68.57

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Asensus Surgical, Inc. (ASXC) stock surged +0.64%, trading at $0.35 on AMEX, up from the previous close of $0.35. The stock opened at $0.35, fluctuating between $0.35 and $0.35 in the recent session.

Stock Snapshot

0.3457

Prev. Close

94.92M

Market Cap

0.346

Day Low

-1.122258064516129

P/E Ratio

-0.31

EPS (TTM)

-0.24

Cash Flow per Share

0.35

Open

272.84M

Number of Shares

0.3495

Day High

90.08%

Free Float in %

0.13

Book Value

3.94M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Aug 21, 2024	0.35	0.35	0.35	0.35	4M
Aug 20, 2024	0.29	0.35	0.29	0.35	22.15M
Aug 19, 2024	0.30	0.30	0.30	0.30	1.11M
Aug 16, 2024	0.29	0.30	0.29	0.30	1.06M
Aug 15, 2024	0.28	0.29	0.28	0.29	1.82M
Aug 14, 2024	0.31	0.32	0.17	0.28	7.95M
Aug 13, 2024	0.32	0.32	0.32	0.32	696.41K
Aug 12, 2024	0.31	0.32	0.31	0.32	839.23K
Aug 09, 2024	0.32	0.32	0.31	0.31	1.34M
Aug 08, 2024	0.31	0.32	0.31	0.32	1.01M
Aug 07, 2024	0.32	0.32	0.31	0.31	4.02M
Aug 06, 2024	0.32	0.33	0.31	0.32	1.92M
Aug 05, 2024	0.31	0.32	0.31	0.32	1.71M
Aug 02, 2024	0.33	0.33	0.32	0.32	2.09M
Aug 01, 2024	0.33	0.34	0.33	0.33	2.66M
Jul 31, 2024	0.34	0.34	0.33	0.33	1.86M
Jul 30, 2024	0.34	0.34	0.34	0.34	1.19M
Jul 29, 2024	0.34	0.34	0.34	0.34	1.43M
Jul 26, 2024	0.34	0.34	0.34	0.34	633.91K
Jul 25, 2024	0.34	0.34	0.34	0.34	686.83K

Contact Details

Durham, NC 27703

United States

https://www.asensus.com 919 765 8400

About Company

Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.

Stock Peers

ELMD

-0.39-1.40%

Electromed, Inc.$27.50 POAS

-0.05-1.58%

Phaos Technology Holdings (Caym$3.12 CATX

0.125+5.15%

Perspective Therapeutics, Inc.$2.55 VTAK

-0.08-3.83%

Catheter Precision, Inc.$2.01 PMI

-0.08-4.28%

Picard Medical, Inc.$1.79 XTNT

-0.0242-3.70%

Xtant Medical Holdings, Inc.$0.63 RMED

0.054+10.00%

Ra Medical Systems, Inc.$0.59

Company Overview

The stock is currently mid-range between its 52-week high and low $0.17 and $0.40. With a market capitalization of about $94.92 million, Asensus Surgical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.38). Key stats such as the average daily volume over the past year has been around 3.26 million shares, in line with its 52-week average. Headquartered in Durham, NC, Asensus Surgical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Anthony Fernando, the company employs approximately 207 people and listed since August 06, 1991. Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia.

Technical Performance

ASXC has shown sold momentum, gaining 24.25% over the past week and 40.28% over the past quarter, though year-to-date performance is up 9.09%. Short-term trend indicators are mixed aligned (SMA20 8.45%, SMA50 5.9%, SMA200 21.53%). The stock’s 14-day RSI is 63.19 (firm momentum), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -12.87% below its high and over 105.86% above its low.

Valuation Metrics

Asensus Surgical, Inc. trades at a P/E ratio of -1.11, slightly below the S&P 500 average, with a price-to-sales ratio of 11.07 and a price-to-book ratio of 2.6 suggesting the stock is closer to book value. The P/FCF stands at -1.48, also above market averages.

Dividend & Fair Value

Asensus Surgical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.22. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Asensus Surgical, Inc. generated EPS of -$0.31 over the past year. Five-year average earnings growth is 39.5%. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at $nan. Next year's EPS is expected at $26.98. Asensus Surgical, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2024, missed forecasts by 40.0%. The prior quarter beat by 40.0%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in February 29, 2024.

Shareholding & Insider Activity

Asensus Surgical, Inc. has 272.84 million shares outstanding. The public float is 245.78 million shares, elevated short interest at 4.23% of float. This equals 11.29 million shares. The short ratio is 7.11 days. SOFAR, S.p.A holds 19.27 million shares, AISLING CAPITAL III LP has 8.34 million shares and Dougherty Dennis has 3.94 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Asensus Surgical generated $8.58M in revenue, or $0.03 per share. Gross margin was -58.66%, operating margin -910.92%, and net profit margin -914.46%. Returns are negative, with ROA at -129.57% and ROE at -234.73%.
On valuation metrics, Asensus Surgical trades at a P/E of -1.11, P/S of 11.07 and P/B of 2.60. The current ratio is 2.88 and quick ratio is 2.31. Operationally, the company’s inventory turnover is 1.83 and cash conversion cycle is 233.27 days. Debt-to-equity is 0.17, supported by a cash flow-to-debt ratio of -11.20.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Asensus Surgical posted revenue of $8.58M, down slightly from $7.09M in the prior quarter. Gross profit was - $5.03M (margin -58.66%). Operating income was - $78.13M (margin -910.9%). Net income was- $78.43M (EPS - $0.31).
The company ended the quarter with $21.07M in cash and short-term investments, a total debt of $5.68M, and net debt of - $11.41M. Total assets were $60.53M, with equity of $33.41M. Financials further reflected weakness, with operating cash flow of - $63.63M, free cash flow of - $64.19M, and capital expenditures of - $561.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Asensus Surgical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -10.89%, with price expected at $0.31 by September 04, 2024, within a range of $0.31 to $0.32 3-Month Outlook: Projected rise of 55.22%, reaching $0.54 by November 19, 2024, with a range of $0.52 to $0.56. 1-Year Outlook: Projected gain of 940.53%, with price at $3.62 by August 21, 2025, within a range of $0.00 to $3.79.

Key Takeaways

Asensus Surgical, Inc. (AMEX:ASXC) shares are flat 9.09% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Asensus Surgical, Inc. trading at a premium to the broader market with a P/E of -1.11. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $2.31, suggesting 563.98% upside. Our AI forecast model points to short-term weakness (-10.89% over two weeks), a medium-term rise (55.22% over three months), and a longer-term gain (940.53% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Asensus Surgical, Inc. (ASXC) stock price?

Asensus Surgical, Inc. (AMEX: ASXC) stock price is $0.35 in the last trading session. During the trading session, ASXC stock reached the peak price of $0.35 while $0.35 was the lowest point it dropped to. The percentage change in ASXC stock occurred in the recent session was 0.64% while the dollar amount for the price change in ASXC stock was $0.00.

ASXC's industry and sector of operation?

The AMEX listed ASXC is part of Medical - Devices industry that operates in the broader Healthcare sector. Asensus Surgical, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ASXC?

Mr. Shameze Rampertab B.Sc. MBA, CA, CPA
Executive Vice President & Chief Financial Officer
Mr. Joshua B. Weingard
Chief Legal Officer & Sec.
Mr. Paul Ziegler Jr., J.D.
Vice President of Sales
Ms. Amanda Owens
Vice President of People
Dr. Stephanie M. Fitts Ph.D.
Vice President of Clinical, Quality and Regulatory Affairs
Mr. Ethan Loiselle
Vice President of Global Marketing
Mr. Anthony Fernando
Pres, Chief Executive Officer & Director
Mr. Ravi Kommineni
Head of Global Quality & Regulatory

How ASXC did perform over past 52-week?

ASXC's closing price is 105.86% higher than its 52-week low of $0.17 where as its distance from 52-week high of $0.40 is -12.87%.

How many employees does ASXC have?

Number of ASXC employees currently stands at 207.

Link for ASXC official website?

Official Website of ASXC is: https://www.asensus.com

How do I contact ASXC?

ASXC could be contacted at phone 919 765 8400 and can also be accessed through its website. ASXC operates from 1 TW Alexander Drive, Durham, NC 27703, United States.

How many shares of ASXC are traded daily?

ASXC stock volume for the day was 3.94M shares. The average number of ASXC shares traded daily for last 3 months was 3.26M.

What is the market cap of ASXC currently?

The market value of ASXC currently stands at $94.92M with its latest stock price at $0.35 and 272.84M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	207
Beta	1.38
Sales or Revenue	$8.58M
5Y Sales Change%	-0.977%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

ASXC Company Profile and Key Details

Asensus Surgical

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Company Overview

Dividend & Fair Value

Valuation Metrics